A review of nutrition in human immunodeficiency virus infection in the era of highly active antiretroviral therapy

Nutrition in Clinical Practice

Volumn 19, Issue 4, 2004, Pages 340-355

  Coyne Meyers, Kristen ^a   Trombley, Lisa E ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIRETROVIRUS AGENT; ASCORBIC ACID; GLUTAMINE; MINERAL; RETINOL; SELENIUM; TRACE ELEMENT; VITAMIN; VITAMIN B GROUP; ZINC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALTERNATIVE MEDICINE; BODY WEIGHT; CALORIC INTAKE; CHRONIC DISEASE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIETARY INTAKE; ENERGY METABOLISM; ENTERIC FEEDING; FEEDING; HARRIS BENEDICT EQUATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERMETABOLISM; MEDICAL DOCUMENTATION; MEDLINE; META ANALYSIS; METABOLIC DISORDER; MINERAL BALANCE; MORTALITY; NUTRITION; NUTRITIONAL COUNSELING; NUTRITIONAL DISORDER; NUTRITIONAL SUPPORT; OUTCOMES RESEARCH; PARENTERAL NUTRITION; PATIENT COUNSELING; PROTEIN INTAKE; QUALITY OF LIFE; RECOMMENDED DAILY INTAKE; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION; WASTING SYNDROME; WEIGHT REDUCTION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 3242658913     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426504019004340     Document Type: Review

References (145)

1. Kotler DP. Nutritional alterations associated with HIV infection. J Acquir Immun Defic Syndr Hum Retrovirol. 2000;25(Suppl): S81-S87.
2. Kotler DP. Human immunodeficiency virus-related wasting: malabsorption syndromes. Semin Oncol. 1998;25(Suppl):S70-S75.
3. Mulligan K, Tai V, Schambelan M. Energy expenditure in human immunodeficiency virus infection. N Engl J Med. 1997; 336:70-71.
4. Wanke CE, Silva M, Ganda A, et al. Role of acquired immune deficiency syndrome-defining conditions in human immunodeficiency virus-associated wasting. Clin Infect Dis. 2003;37(Suppl 2):S81-S84.
5. Milberg J, Sharma R, Scott F, Conviser R, Marconi K, Parham D. Factors associated with delays in accessing HIV primary care in rural Arkansas. AIDS Pt Care STDS. 2001;15:527-532.
6. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States and results from the HIV Cost and Services Utilization Study. JAMA. 1999;281: 2305-2315.
7. Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach S. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:230-236.
8. Batterham MJ, Garsia R, Greenop P. Prevalence and predictors of HIV-associated weight loss in the era of highly active antiretroviral therapy. Int J STD AIDS. 2002;13:744-747.
9. Salomon J, De TP, Melchior JC. Nutrition and HIV infection. Br J Nutr. 2002;87(Suppl 1):S111-S119.
10. Steinhart CR. HIV-associated wasting in the era of HAART: a practice-based approach to diagnosis and treatment. AIDS Read. 2001;11:557-560, 566-569.
11. Panel on Clinical Practices for the Treatment of HIV. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep. 1998;47(RR-5): 1-41, updated November 10, 2003. Available at: http://www. cdc.gov/mmwr/preview/mmwrhtml/00052295.htm. Accessed June 14, 2004.
12. Currier J, Carpenter C, Daar E, Kotler D, Wanke C. Identifying and managing morphologic complications of HIV and HAART. AIDS Read. 2002;12:114-119, 124-125.
13. Woods MN, Spielgelman D, Knox TA, et al. Nutrient intake and body weight in a large HIV cohort that includes women and minorities. J Am Diet Assoc. 2002;102:203-211.
14. Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDS. 2001;15:411-423.
15. American Dietetic Association. Position of the American Dietetic Association and Dietitians of Canada: nutrition intervention in the care of persons with human immunodeficiency virus infection. J Am Diet Assoc. 2000;100:708-717.
16. Los Angeles County Commission on HIV Health Services (LACCHHS). Guidelines for Implementing HIV Medical Nutrition Therapy Guidelines. Los Angeles, CA: 1999. Available at: http://www.numedx.com/readstory.phtml?story= v2n3feature. Accessed June 14, 2004.
17. Federation of American Societies for Experimental Biology, Life Sciences Research Office. Third Report on Nutrition Monitoring in the United States. Vol. 2. Washington, DC: US Government Printing Office; 1995.
18. th edition. Washington, DC: National Academy Press; 1989.
19. Macallan DC, Noble C, Baldwin C. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med. 1995;333:83-88.
20. Batterham MJ, Morgan-Jones J, Greenop P, Garsia R, Gold J, Caterson I. Calculating energy requirements for men with HIV/AIDS in the era of highly active antiretroviral therapy. Eur J Clin Nutr. 2003;57:209-217.
21. Lane BJ, Provost-Craig MA. Resting energy expenditure in asymptomatic HIV-infected females. J Womens Health Gend Based Med. 2000;9:321-327.
22. Grinspoon S, Corcoran C, Miller K, et al. Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr. 1998;68:720-725.
23. Centers for Disease Control and Prevention. Revision of the CDC surveillance definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1987;36(Suppl):3S-15S.
24. Harris JA, Benedict FG. A biometric study of basal metabolism in man. Publication no. 279. Washington, DC: Carnegie Institute of Washington; 1919: 1-266.
25. Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr. 1985; 39(Suppl)S5-S41.
26. Cunningham JJ. Body composition as a determinant of energy expenditure: a synthetic review and a proposed general prediction equation. Am J Clin Nutr. 1991;54:963-969.
27. Melchior JC, Salmon D, Rigaud D, et al. Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr. 1991;53:437-441.
28. Melchior JC, Raguin G, Boulier A, et al. Resting energy expenditure in human immunodeficiency virus-infected patients: comparison between patients with and without secondary infections. Am J Clin Nutr. 1993;57:614-619.
29. Schwenk A, Steuck H, Kremer G. Oral supplements as adjunctive treatment to nutritional counseling in malnourished HIV-infected patients: randomized controlled trial. Clin Nutr. 1999; 18:371-374.
30. Pernerstorfer-Schoen H, Schindler K, Parschalk B, et al. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS. 1999;13:2389-2396.
31. Roubenoff R, Grinspoon S, Skonik PR, et al. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. Am J Physiol Endocrinol Metab. 2002;283:E138-E145.
32. Grunfeld C, Pang M, Shimizu L, Shigenanga JK, Jensen P, Feingold KR. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr. 1992;55:455-460.
33. Kosmiski LA, Kuritzkes DR, Sharp TA, et al. Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome. Metabolism. 2003;52:620-625.
34. Williams BS, Barsch G, Muurahainen N, Collins G, Subhasree Sr, Wheeler D, for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Protein intake is positively associated with body cell mass in weight-stable HIV-infected men. J Nutr. 2003; 133:1143-1146.
35. McCorkindale C, Dybevik K, Coulston AM, Sucher KP. Nutritional status of HIV-infected patients during the early disease stages. J Am Diet Assoc. 1990;90:1236-1241.
36. Dworkin BM, Wormser GP, Axelrod F, et al. Dietary intake in patients with acquired immunodeficiency syndrome (AIDS), patients with AIDS-related complex, and serologically positive human immunodeficiency virus patients: correlations with nutritional status. JPEN. 1990;14:605-609.
37. DiFranco MG, Woods M, Spiegelman D, Knox T, Gorbach S. Nutritional correlates with CD4 counts in HIV-infected individuals [abstract]. XI international AIDS conference. July 9-12, 1996, Vancouver, BC.
38. British Columbia Centre for Excellence in HIV/AIDS. Therapeutic guidelines for HIV/AIDS and related conditions. Available at: http://www.aidsnutrition.org. Accessed February 4, 2004.
39. New York State Department of Health. Criteria for the Medical Care of Adults with HIV. New York, NY: New York State Department of Health; 2001.
40. The American Dietetic Association. Nutrition management of HIV infection and AIDS. In: Goot SA, Chapman KM, Furman JA, et al., eds. American Manual of Clinical Dietetics. 5th ed. Chicago, Ill: The American Dietetic Association; 1996:388.
41. Institute of Medicine Nutrient Recommendations. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (Institute of Medicine Web site). Available at: http://www.iom.edu/ report.asp?id=4340. Accessed February 1, 2004.
42. Beisel WR. Single nutrients and immunity. Am J Clin Nutr. 1982;35:417-468.
43. Chandra RK, Newberne PM. Nutrition Immunity and Infection: Mechanisms of Interactions. New York, NY: Plenum Press; 1977.
44. Dreizen S. Nutrition and the immune response: a review. Int J Vitam Nutr Res. 1979;49:220-228.
45. Fawzi W. Micronutrients and human immunodeficiency virus type 1 disease progression among adults and children. Clin Infect Dis. 2003;37(Suppl):S112- S116.
46. Keusch GT, Thea DM. Manlutrition in AIDS. Med Clin North Am. 1993;77:795-814.
47. Tang AM, Graham NMH, Semba RD, Saah AJ. Association between serum vitamin A and E levels and HIV-1 disease progression. AIDS. 1997;11:613-620.
48. Baum MK, Shor-Posner G, Lu Y, et al. Micronutrients and HIV-1 disease progression. AIDS. 1995;9:1051-1056.
49. Tang AM, Graham NMH, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. Am J Epidemiol. 1996;143:1244-1256.
50. Abrams B, Duncan D, Hertz-Picciotto I. A prospective study of dietary intake and acquired immune deficiency syndrome in HIV-seropositive homosexual men. J Acquir Immune Defic Syndr. 1993;6:949-958.
51. Tang AM, Graham NMH, Kirby AJ, McCall AD, Willett WC, Saah AJ. Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome in homosexual men. Am J Epidemiol. 1993;138:1-15.
52. Harriman GR, Smith PD, Horne MK, et al. Vitamin B12 malabsorption in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1989;149:2039-2041.
53. Kieburtz KD, Giang DW, Schiffer RD, Vakil N. Abnormal vitamin B12 metabolism in human immunodeficiency virus infection: association with neurological dysfunction. Arch Neurol. 1991;48:312-314.
54. Beach RS, Morgan R, Wilkie F, et al. Plasma vitamin B12 level as a potential cofactor in studies of human immunodeficiency virus type 1-related cognitive changes. Arch Neurol. 1992;49: 501-506.
55. Sackler N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS cohort study, 1990-1998. Neurology. 2001;56:257-260.
56. Dore GJ, Correll Pk, Li Y, et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999;13:1249-1253.
57. Remacha, AF, Riera A, Cadafalch J, Gimferrer E. Vitamin B12 abnormalities in HIV infected patients. Eur J Haematol. 1991; 47:60-64.
58. Herzlich BC, Schiano TD, Moussa Z, Zimbalist E, Panagopoulos G, Nawabi I. Decreased intrinsic factor secretion in AIDS: relation to parietal cell acid secretory capacity and vitamin B12 malabsorption. Am J Gastroenterol. 1992;87:1781-1788.
59. Woods MN, Tang AM, Forrester J, et al. Effect of dietary intake and protease inhibitors on serum vitamin B12 levels in a cohort of human immunodeficiency virus-positive patients. Clin Infect Dis. 2003;37(Suppl):S124- S131.
60. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu Rev Nutr. 1999;19:357-377.
61. Remacha AF, Cadafalch J, Sard P, Barcelo M, Fuster M. Vitamin B-12 metabolism in HIV-infected patients in the age of highly active antiretroviral therapy: role of homocysteine in assessing vitamin B-12 status. Am J Clin Nutr. 2003;77:420-424.
62. Christen WG, Ajani UA, Glynn RJ, Henekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease. Arch Intern Med. 2000;160:422-434.
63. Paltiel O, Falutz J, Veilleux M, Rosenblatt DS, Gordon K. Clinical correlations of subnormal vitamin B-12 levels in patients infected with the human immunodeficiency virus. Am J Hematol. 1995;49:318-322.
64. Herbert V, Fong W, Gulle V, Stopler T. Low holotranscobalamin II is the earliest serum marker for subnormal vitamin B-12 absorption in patients with AIDS. Amer J Hematol. 1990;34: 132-139.
65. Semba RD. Vitamin A, immunity, and infection. Clin Infect Dis. 1994;19:489-499.
66. Sommer A, Katz J, Tarwotjo I. Increased risk of respiratory disease and diarrhea in children with pre-existing mild vitamin A deficiency. Am J Clin Nutr. 1984;40:1090-1095.
67. Semba RD, Caiaffa WT, Graham NM, Cohn S, Vlahov D. Vitamin A deficiency and wasting as predictors of mortality in human immunodeficiency virus-infected injection drug users. J Infect Dis. 1995;171:1196-1202.
68. Fawzi WW, Msamanga GI, Spiegelman D, et al. Randomized trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Lancet. 1998;351:1477-1482.
69. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM. Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa: South African Vitamin A Study Group. AIDS. 1999;13:1517-1524.
70. Villamor E, Msamanga G, Spiegelman D, et al. Effect of multi-vitamin and vitamin A supplements on weight gain during pregnancy among HIV-1-infected women. Am J Clin Nutr. 2002;76:1082-1090.
71. Fawzi WW, Msamanga GI, Hunter D, et al. Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS. 2002;16: 1935-1944.
72. Linder MC. Nutrition and metabolism of vitamins. In: Linder MC, ed. Nutritional Biochemistry and Metabolism with Clinical Applications. New York, NY: Elsevier; 1991:111-189.
73. Ullrich R, Schneider T, Heise W, et al, for the Berlin Diarrhoea/Wasting Syndrome Study Group. Serum carotene deficiency in HIV-infected patients. AIDS. 1994;8:661-665.
74. Tang AM, Smit E, Semba RD, et al. Improved antioxidant status among HIV-infected injecting drug users on potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;23:321-326.
75. Coodley GO, Coodley MK, Lusk R, et al. Beta-carotene in HIV infection: An extended evaluation. AIDS. 1996;10:967-973.
76. Nimmagadda AP, Burri BJ, Neidlinger T, O'Brien WA, Goetz MB. Effect of oral beta-carotene supplementation on plasma human immunodeficiency virus (HIV) RNA levels and CD4+ cell counts in HIV-infected patients. Clin Infect Dis. 1998;27:1311-1313.
77. Gavrila A, Tsiodras S, Doweiko J, et al. Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study. Clin Infect Dis. 2003;36:1593-1601.
78. Allard JP, Aghdassi E, Chau J, et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. AIDS. 1998;12:1653-1659.
79. Jaruga P, Jaruga B, Gackowshi D, et al. Supplementation with antioxidant vitamins prevents oxidative modification of DNA in lymphocytes of HIV-infected patients. Free Radic Biol Med. 2002;32:414-420.
80. Spada C, Treitinger A, Reis M, et al. An evaluation of antiretroviral therapy associated with alpha-tocopherol supplementation in HIV-infected patients. Clin Chem Lab Med. 2002;40:456-459.
81. Lopez O, Bonnefont-Rousselot D, Edeas M, Emerit J, Bricaire F. Could antioxidant supplementation reduce antiretroviral therapy induced chronic stable hyperlactatemia? Biomed Pharmacother. 2003;57:113-116.
82. Batterham M, Gold J, Naidoo D, et al. A preliminary open label dose comparison using an antioxidant regimen to determine the effect on viral load and oxidative stress in men with HIV/AIDS. Eur J Clin Nutr. 2001;55:107-114.
83. McDermid JM, Lalonde RD, Gray-Donald K, Baruchel S, Kubow S. Associations between dietary antioxidant intake and oxidative stress in HIV-seropositive and HIV-seronegative men and women. J Acquir Immune Defic Syndr. 2002;29:158-164.
84. Shor-Posner G, Miguez MJ, Pineda LM, et al. Impact of selenium status on the pathogenesis of mycobacterial disease in HIV-1 infected drug users during the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:169-173.
85. Baum MK, Shor-Posner G, Lai S, et al. High risk of HIV-related mortality is associated with selenium deficiency. J AIDS Hum Retro. 1997;15:370-374.
86. Keen CL, Gershwin ME. Zinc deficiency and immune function. Annu Rev Nutr. 1990;10:415-431.
87. Sherman AR. Zinc, copper, and iron nutriture and immunity. J Nutr. 1992;122:604-609.
88. Ripa S, Ripa R. Zinc and immune function. Minerva Med. 1995;86:315-318.
89. Lai H, Lai S, Shor-Posner G, Ma F, Trapido E, Baum MK. Plasma zinc, copper, copper:zinc ratio, and survival in a cohort of HIV-1 infected homosexual men. J Acquir Immune Defic Syndr. 2001;27:56-62.
90. Baum MK, Shor-Posner G, Campa A. Zinc status in human immunodeficiency virus infection. J Nutr. 2000;130(5 Suppl): 1421S-1423S.
91. Razzini E, Baronzio GF. Omega-3 fatty acids as coadjuvant treatment in AIDS. Med Hypotheses. 1993;41:300-305.
92. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorders. Am J Psychiatry. 2002;159:477-479.
93. Carroll DN, Roth MT. Evidence for the cardioprotective effects of omega-3 fatty acids. Ann Pharmacother. 2002;36:1950-1956.
94. New guidelines focus on fish oil, ω-3 fatty acids. FDA Consum. 2003;37:7. Available at: http://www.fda.bov/fdac/departs/2003/103_note.html. Accessed June 14, 2004.
95. Shabert JK, Wilmore DW. Glutamine deficiency as a cause of human immunodeficiency virus wasting. Med Hypotheses. 1996; 46:252-256.
96. Kotler DP, Tierney AR, Wang J, Pierson Jr RN. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989;50:444.
97. Shabert JK, Winslow C, Lacey JM, Wilmore DW. Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Nutrition. 1999;15:860-864.
98. Noyer CM, Simon D, Borczuk A, Brandt L, Lee MJ, Nehra N. A double-blind placebo-controlled pilot study of glutamine therapy for abnormal intestinal permeability in patients with AIDS. Am J Gastroenterol. 1998;93:972-975.
99. Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using β-hydroxy β-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo controlled study. JPEN. 2000;24:133-139.
100. Association of Nutrition Services Agencies. Nutrition guidelines for agencies providing food to people living with HIV disease. Available at: http://www.aidsnutrition.org. Accessed February 5, 2004.
101. HIV/AIDS Bureau. Ryan White CARE Act Title III Program and Application Guidance for New Competing Proposals. Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau. Washington, DC; 2001.
102. Nerad J, Romeyn M, Silverman E, et al. General nutrition management in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36(Suppl 2):S52-S62.
103. Rabeneck L, Palmer A, Knowles JB, et al. A randomized controlled trial evaluating nutrition counseling with or without oral supplementation in malnourished HIV-infected patients. J Am Diet Assoc. 1998;98:434-438.
104. Kotler DP. Editorial: nutritional support in AIDS. Am J Gastroenterol. 1991;86:539-541.
105. Gasparis AP, Tassiopolous AK. Nutritional support in the patient with HIV infection. Nutrition. 2001;17:981-982.
106. American Gastroenterological Association. American Gastroenterological Association medical position statement: guidelines for the management of malnutrition and cachexia, chronic diarrhea, and hepatobiliary disease in patients with human immunodeficiency virus infection. Gastroenterology. 1996;111:1722-1723.
107. Berneis K, Battegay M, Bassetti S, et al. Nutritional supplements combined with dietary counseling diminish whole body protein catabolism in HIV-infected patients. Eur J Clin Invest. 2000;30:87-94.
108. Keithley JK, Swanson B, Zeller JM, et al. Comparison of standard and immune-enhancing oral formulas in asymptomatic HIV-infected persons: a multicenter randomized controlled clinical trial. JPEN. 2002;26:6-14.
109. Hoh R, Pelfini A, Neese RA, et al. De novo lipogenesis predicts short-term body-composition response by bioelectric impedance analysis to oral nutritional supplements in HIV-associated wasting. Am J Clin Nutr. 1998;68:154-163.
110. de Luis Roman DA, Bachiller P, Izaolo O, et al. Nutritional treatment for acquired immunodeficiency virus infection using an enterotropic peptide-based formula enriched with n-3 fatty acids: a randomized prospective trial. Eur J Clin Nutr. 2001;55: 1048-1052.
111. Chlebowski RT, Beall G, Grosvenor M, et al. Long-term effects of early nutritional support with new enterotropic peptide-based formula vs. standard enteral formula in HIV-infected patients: randomized prospective trial. Nutrition. 1993;9:507-512.
112. Ockenga J, Suttmann, Selberg O, et al. Percutaneous endoscopic gastrostomy in AIDS and control patients: risks and outcome. Am J Gastroenterol. 1996;91:1817-1822.
113. Kotler DP, Tierney AR, Ferraro R, et al. Enteral alimentation and repletion of body cell mass in malnourished patients with acquired immunodeficiency syndrome. Am J Clin Nutr. 1991;53: 149-154.
114. Kotler DP, Fogleman L, Tierney AR. Comparison of total parenteral nutrition (TPN) and an oral, semielemental diet on body composition, physical function, and nutrition-related costs in patients with malabsorption due to acquired immunodeficiency syndrome. JPEN. 1998;22:120-126.
115. Melchior JC, Chastang C, Gelas P, et al. Efficacy of 2-month TPN in AIDS patients: a controlled randomized prospective trial. AIDS. 1996;10:379-384.
116. Ellis W, Basinger G, Paul J, Swails WS, Bell SJ, Forse RA. The use of home TPN in a patient with AIDS. AIDS Patient Care. 1994;6-10.
117. Melchior JC, Gelas P, Carbonnel F, et al. Improved survival by home TPN in AIDS patients: follow up of a controlled randomized prospective trial. AIDS. 1998;12:336-337.
118. Ashley C, Howard L. Evidence base for specialized nutrition support. Nutr Rev. 2000;58:282-289.
119. Knowles JB, Gilmore N. Discontinuation of TPN in a patient with acquired immunodeficiency syndrome: a Canadian perspective. Nutr Rev. 1994;52:271-274.
120. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726-735.
121. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
122. Puls RL, Carr A. Practical applications of the HIV lipodystrophy case definition. AIDS Read. 2003;13:480-492.
123. Thiebaut R, Dequae-Merchadou L, Ekouevi DK, et al. Incidence and risk factors of severe hypertriglyceridemia in the era of highly active antiretroviral therapy: The Aquitaine Cohort, France, 1996-99. HIV Med. 2001;2:84-88.
124. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis. 2000;31:1482-1487.
125. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1 infected patients treated with protease inhibitors. AIDS. 2000;14:F123-F128.
126. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-1398.
127. Kotler DP, Rosenbaum K, Wang J, et al. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol. 1999; 20:228-237.
128. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
129. Carr A, Miller J, Law L, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25-F32.
130. Miller JE, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293-301.
131. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet. 1999; 353:2093-2099.
132. Currier J. Management of metabolic complications of therapy. AIDS. 2002;16(Suppl 4):S171-S176.
133. Shevitz AH, Knox TA. Nutrition in the era of highly active antiretroviral therapy. Clin Infect Dis. 2001;32:1769-1775.
134. Fetrow CW, Avila JR. Professional's Handbook of Complementary and Alternative Medicines. Springhouse, PA: Springhouse Corporation; 1999.
135. Swanson B, Keithley JK, Zeller JM, Cronin-Stubbs D. Complementary and alternative therapies to manage HIV-related symptoms. J Assoc Nurs AIDS Care. 2000;11:40-60.
136. Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med. 1998;158:2257-2264.
137. Agnoletto V, Chiaffarino F, Nasta P, Rossi R, Parazzini F. Reasons for complementary therapies and characteristics of users among HIV-infected people. Int J STD AIDS. 2003;14: 482-486.
138. Standish LJ, Greene KB, Bain S, et al. Alternative medicine use in HIV-positive men and women: Demographics, utilization patterns and health status. AIDS Care. 2001;13:197-208.
139. Elion RA, Cohen C. Complementary medicine and HIV infection. Complement Alternat Ther Primary Care. 1997;24:905-919.
140. MacIntyre RC, Holzemer WL. Complementary and alternative medicine with HIV/AIDS, part II: selected literature review. J Assoc Nurs AIDS Care. 1997;8:25-38.
141. Piscitelli SC, Burstein AH, Welden N, Gallicano, KD, Falloon J. The effect of garlic on the pharmacokinetics of saquinavir. Clin Infect Dis. 2002;34:234-238.
142. Sussman E. Garlic supplements can impede HIV medication. AIDS. 2000;16:N5.
143. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet. 2000;355:547-548.
144. rd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 14-17, 2003, Chicago, IL. Available at: http://www.hivandhepatitis.com/recent/ alternative/100103b.html. Accessed January 31, 2004.
145. Fenton M, Silverman E, Vazzo L. HIV/AIDS adults. In: Gilbreath J, Inman-Felton AE, Johnson E, Robinson G, Smith K, eds. Medical Nutrition Therapy Across the Continuum of Care. 2nd ed. Chicago, IL: The American Dietetic Association; 1998: 1-16.